← Back to Search

Anticoagulant

Rivaroxaban for Heart Attack (R2MI Trial)

Phase 2 & 3
Waitlist Available
Led By Michelle Graham, MD
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, estimated at 1-year

Summary

This trial is testing whether a drug can help prevent major heart problems in people who have had a heart attack.

Eligible Conditions
  • Heart Attack

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, estimated at 1-year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, estimated at 1-year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility outcome
Secondary study objectives
Number of participants who experience a composite of death, stroke or myocardial infarction
Number of participants who experience major bleeding

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: RivaroxabanActive Control1 Intervention
Rivaroxaban 2.5mg oral twice daily for 90-days
Group II: PlaceboPlacebo Group1 Intervention
Oral placebo tablet twice daily for 90-days

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor
936 Previous Clinical Trials
433,819 Total Patients Enrolled
Michelle Graham, MDPrincipal InvestigatorUniversity of Alberta
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top